The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

In December, the U.S.-based National Academy of Sciences published a report classifying myopia, for the first time, as a ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...

Sydnexis, Inc. ( a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...

Paediatric ophthalmologist, Dr Katie Williams, discusses her research exploring factors associated with myopia ...

Medically reviewed by Matthew Wosnitzer, MD Erectile dysfunction (ED) is an inability to achieve or maintain an erection ...

Benjamin Ayodele walked into the Federal Teaching Hospital Lokoja on January 19, 2025, with hope in his eyes, determined to ...

Optometrists are more likely to report AI-generated chatbot responses concerning myopia as favorable than optometry students.